tbuckley/cabot-search huggingface dataset:
Current Medical Literature
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Joint association of food nutritional profile by Nutri-Score front-of-pack label and ultra-processed food intake with mortality: Moli-sani prospective cohort study
Authors: Marialaura Bonaccio, Augusto Di Castelnuovo, Emilia Ruggiero, Simona Costanzo, Giuseppe Grosso, Amalia De Curtis, Chiara Cerletti, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello
Journal: BMJ (2022)

To jointly analyse two food dimensions, the Food Standards Agency Nutrient Profiling System (FSAm-NPS), used to derive the Nutri-Score front-of-pack label, and the NOVA classification in relation to mortality.Prospective cohort study.Moli-sani Study, Italy 2005-10.22 895 participants (mean age 55 (SD 12) years; 48% men).Associations between dietary exposures and mortality risk, assessed using multivariable cause specific Cox proportional hazard models controlled for known risk factors.A total of 2205 deaths occurred during 272 960 person years of follow-up. In the highest quarter of the FSAm-NPS index compared with the lowest quarter, multivariable adjusted hazard ratios for all cause and cardiovascular mortality were 1.19 (95% confidence interval 1.04 to 1.35; absolute risk difference 4.3%, 95% confidence interval 1.4% to 7.2%) and 1.32 (1.06 to 1.64; 2.6%, 0.3% to 4.9%), respectively. The hazard ratios were 1.19 (1.05 to 1.36; absolute risk difference 9.7%, 5.0% to 14.3%) and 1.27 (1.02 to 1.58; 5.0%, 1.2% to 8.8%), respectively, for all cause and cardiovascular mortality when the two extreme categories of ultra-processed food intake were compared. When these two indices were analysed jointly, the magnitude of the association of the FSAm-NPS dietary index with all cause and cardiovascular mortality was attenuated by 22.3% and 15.4%, respectively, whereas mortality risks associated with high ultra-processed food intake were not altered.Adults with the lowest quality diet, as measured using the FSAm-NPS dietary index (underpinning the Nutri-Score), and the highest ultra-processed food consumption (NOVA classification) were at the highest risk for all cause and cardiovascular mortality. A significant proportion of the higher mortality risk associated with an elevated intake of nutrient poor foods was explained by a high degree of food processing. In contrast, the relation between a high ultra-processed food intake and mortality was not explained by the poor quality of these foods.
Mycoplasma and Rheumatoid Arthritis
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Central Nervous System Stimulant (Deanol) on Behavior
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Journal: JAMA (2013)

On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants. PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23, Merck & Co. Inc.), the vaccine currently recommended for these groups of adults. The evidence for the benefits and risk of PCV13 vaccination of adults with immunocompromising conditions was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and designated as a Category A recommendation. This report outlines the new ACIP recommendations for PCV13 use; explains the recommendations for the use of PCV13 and PPSV23 among adults with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants; and summarizes the evidence considered by ACIP to make its recommendations.
The Challenge of Chronic Diseases.
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Screening for Suicide Risk: Recommendation and Rationale
Journal: Annals of Internal Medicine (2004)

This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for suicide risk and the supporting scientific evidence and updates the 1996 recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the systematic evidence review on this topic, which is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov). The complete recommendation statement and the summary of the evidence are also available from the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, ahrqpubs@ahrq.gov). *For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
Topical Effect of Acriflavine Compounds on Growth and Spread of Malignant Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Horace Goldie, Matthew Walker, Theodore Graham, Frank Williams
Journal: JNCI Journal of the National Cancer Institute (1959)

Routine tests of presumably antitumor agents, by assaying their ability to induce regression of tumor tissue and to increase the lifespan of the host, were supplemented by methods that had as test objectives (1) growth of free tumor cells in ascitic fluid, (2) implantation from this fluid into visceral and parietal peritoneum and adjacent tissues, and (3) spread and growth of experimentally infiltrated tumor cells in anatomically sharply circumscribed areas of the skin (the scalp and the scrotum), which allowed a quantitative estimate of these phenomena. Neutral acriflavine was selected for trial on account of (1) its antimetabolite effect against adenine-containing factors in bacteria and protozoa, which resulted in suppression of their viability; (2) its abundant storage in injected tissue at a therapeutic topical dose level; (3) its low systemic toxicity. The use of these methods demonstrated that acriflavine (1) inhibited the viability in vitro of tumor-cell suspensions after 2-hour incubation; (2) arrested completely, in well-tolerated doses, the proliferation of free tumor cells in ascitic fluid and their spread and implantation into peritoneal tissue; (3) prevented growth and spread of tumor cells that infiltrated into the scalp or the scrotum; and (4), in producing this effect, inflicted no visible damage to injected healthy tissue, i.e., it affected selectively tumor cells. The significance of the testing methods used and the value of their results for the clinical application of acriflavine in prevention of tumor-cell spread in tissues are discussed.
Multimodal imaging distribution assessment of a liposomal antibiotic in an infectious disease model
Authors: Shih-Hsun Cheng, M. Reid Groseclose, Cindy Mininger, Mats Bergstrom, Lily Zhang, Stephen C. Lenhard, Tinamarie Skedzielewski, Zachary D. Kelley, Debra Comroe, Hyundae Hong, Haifeng Cui, Jennifer L. Hoover, Steve Rittenhouse, Stephen Castellino, Beat M. Jucker, Hasan Alsaid
Journal: Journal of Controlled Release (2022)

Liposomes are promising targeted drug delivery systems with the potential to improve the efficacy and safety profile of certain classes of drugs. Though attractive, there are unique analytical challenges associated with the development of liposomal drugs including human dose prediction given these are multi-component drug delivery systems. In this study, we developed a multimodal imaging approach to provide a comprehensive distribution assessment for an antibacterial drug, GSK2485680, delivered as a liposomal formulation (Lipo680) in a mouse thigh model of bacterial infection to support human dose prediction. Positron emission tomography (PET) imaging was used to track the in vivo biodistribution of Lipo680 over 48 h post-injection providing a clear assessment of the uptake in various tissues and, importantly, the selective accumulation at the site of infection. In addition, a pharmacokinetic model was created to evaluate the kinetics of Lipo680 in different tissues. Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) was then used to quantify the distribution of GSK2485680 and to qualitatively assess the distribution of a liposomal lipid throughout sections of infected and non-infected hindlimb tissues at high spatial resolution. Through the combination of both PET and MALDI IMS, we observed excellent correlation between the Lipo680-radionuclide signal detected by PET with the GSK2485680 and lipid component signals detected by MALDI IMS. This multimodal translational method can reduce drug attrition by generating comprehensive biodistribution profiles of drug delivery systems to provide mechanistic insight and elucidate safety concerns. Liposomal formulations have potential to deliver therapeutics across a broad array of different indications, and this work serves as a template to aid in delivering future liposomal drugs to the clinic.
Regional Variation in the Incidence of Hip Fracture
Authors: Steven J. Jacobsen
Journal: JAMA (1990)

FRACTURE of the hip is a major cause of morbidity and mortality in persons 65 years of age and older. Incidence rates for hip fracture are known to vary by both sex and race.<sup>1-4</sup>There is also marked variability in hip fracture incidence by geographic region, with the highest rates found in Scandinavia, followed by the United States, Western Europe, Asia, and Africa.<sup>5,6</sup> Within the United States, relatively little is known about the geographic pattern of hip fracture. Most studies have described the incidence of hip fracture for the country as a whole,<sup>2,3</sup>for limited geographic regions,<sup>4,7,8</sup>or by broadly defined Census divisions.<sup>9</sup>This study examines the geographic distribution of hip fracture incidence in the United States at the county level. To this end, data are obtained from the Health Care Financing Administration (HCFA) and the Department of Veterans Affairs (VA) that identify all hospital
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Authors: Mariana I. Capurro, Yun-Yan Xiang, Corrinne Lobe, Jorge Filmus
Journal: Cancer Research (2005)

Abstract Glypican-3 (GPC3) is a heparan sulfate proteoglycan that is bound to the cell membrane by a glycosyl-phosphatidylinositol anchor. GPC3 is expressed by most hepatocellular carcinomas but not by normal hepatocytes and benign liver lesions. We report here that GPC3 stimulates the in vitro and in vivo growth of hepatocellular carcinoma cells by increasing autocrine/paracrine canonical Wnt signaling. Coimmunoprecipitation experiments showed that GPC3 is able to form complexes with Wnts, and cell-binding assays indicated that GPC3-expressing cells have an increased capacity to bind Wnt. Collectively, these results suggest that GPC3 stimulates Wnt activity by facilitating the interaction of this polypeptide with its signaling receptors. Surprisingly, in contrast to the current model that proposes that Wnt-glypican binding is mediated by the heparan sulfate chains, we found that the nonglycanated GPC3 core protein can form complexes with Wnts. Furthermore, we showed that the glycosaminoglycan chains are not required for the stimulatory effect on Wnt signaling and hepatocellular carcinoma growth.
Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp’s Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879–86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer
Authors: Heng Li, Yucong Zhang, Hua Xu
Journal: European Urology (2022)
Statins for the primary prevention of cardiovascular disease
Authors: S. Ebrahim, F. C. Taylor, P. Brindle
Journal: BMJ (2014)

How safe are they?Use of statins by low risk patients has been criticised on the grounds that their benefits do not outweigh their harms 12 and debated. 13 14However, all cause mortality in people taking statins with no pre-existing cardiovascular disease is reduced (table⇓), indicating that any unintended life threatening effects are outweighed by their beneficial impact on cardiovascular disease, although this evidence is not strong. 15Earlier concerns about cancer risk are unfounded. 16However, other unintended effects
Fatal Yellow Fever in a Traveler Returning From Venezuela, 1999
Journal: JAMA (2000)

On September 28, 1999, a previously healthy 48-year-old man from California sought care at a local emergency department (ED) and was hospitalized with a 2-day history of fever (102 F [38.9 C]), chills, headache, photophobia, diffuse myalgias, joint pains, nausea, vomiting, constipation, upper abdominal discomfort, and general weakness. On September 26, he had returned from a 10-day trip to Venezuela. On September 29, an infectious disease physician from the ED contacted the Marin County Health Department (MCHD) about the patient's symptoms; MCHD reported his illness to the California Department of Health Services (CDHS) as a suspected case of viral hemorrhagic fever. This report describes the investigation of the case.
The Relationship Between 'Job Strain,' Workplace Diastolic Blood Pressure, and Left Ventricular Mass Index
Authors: Peter L. Schnall
Journal: JAMA (1990)

To determine whether "job strain" (defined as high psychological demands and low decision latitude on the job) is associated with increased workplace diastolic blood pressure and the left ventricular mass index, we conducted a case-control study at seven urban work sites of 215 employed men aged 30 to 60 years without evidence of coronary heart disease. After comprehensive blood pressure screening of male employees (N = 2556) at the work site, 87 cases of hypertension and a random sample of 128 controls were studied. In a multiple logistic regression model, job strain was significantly related to hypertension, with an estimated odds ratio of 3.1, after adjusting for age, race, body-mass index, type A behavior, alcohol intake, smoking, work site, 24-hour urine sodium excretion, education, and physical demand level of the job. Controlling for the above variables in subjects aged 30 to 40 years with job strain, we found that the echocardiographically determined left ventricular mass index was, on average, 10.8 g/m<sup>2</sup>greater than in subjects without job strain. We conclude that job strain may be a risk factor for both hypertension and structural changes of the heart in working men. (<i>JAMA</i>. 1990;263:1929-1935)
Critical Studies in Neurology
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
β2-Microglobulin Amyloidosis
Authors: Gerhard Lonnemann, Karl M. Koch
Journal: Journal of the American Society of Nephrology (2002)

ABSTRACT. The available data on the pathophysiology of β2-microglobulin amyloidosis (β2mA) suggest that this progressive disease associated with end-stage renal failure develops in several consecutive phases. First, declining kidney function leads to retention of β2 microglobulin (β2m) and its deposition preferentially in the synovial tissue of bigger joints such as wrists, shoulders, and hips. Second, at the site of deposition, formation of unique amyloid fibrils, whose major component is β2m, takes place. Deposition and fibril formation occur in the absence of modification of β2mA by advanced glycoxidation end products and also in the absence of a local inflammatory response. It is later, in the third phase, that advanced glycoxidation end product modification of β2m induces a local inflammatory response by attracting macrophages chemotactically and by stimulating these cells to produce and release proinflammatory cytokines. In addition, unmodified β2m itself induces inflammatory activities such as upregulation of cyclooxygenase-2 and metalloproteinase-1. The severity of the local inflammation seems to determine the degree of the destructive processes in tissue and bone accompanying β2mA.
Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration–Resistant Prostate Cancer: Missing Parts in a Superb Study
Authors: Johann S. de Bono, Christopher Parker, Howard I. Scher, R. Bruce Montgomery, M. Craig Miller, Henk Tissing, Gerald V. Doyle, Leon W.W.M. Terstappen, Kenneth J. Pienta, Derek Raghavan
Journal: Clinical Cancer Research (2009)
Poliomyelitic Paralysis and Tonsillectomy
Authors: Alfred E. Fischer, Pascal F. Lucchesi, Herbert H. Marks, Maxwell Stillerman, Louis Weinstein
Journal: JAMA (1963)

<h3>To the Editor:</h3> —An editorial in the Sept 1, 1962, issue ofThe Journal(<b>181</b>:784), based on an article by Ravenholt entitled "Poliomyelitic Paralysis and Tonsillectomy Reconsidered" in the<i>Amer J Dis Child</i>(<b>103</b>:658 May 1962), gives a distorted picture of the relationship of tonsillectomy to paralytic poliomyelitis. Ravenholt goes far beyond the concept expressed by Fischer, Stillerman, and Marks<sup>1</sup>in using the term "lifelong increased susceptibility," because the paper cited dealt only with a purposely circumscribed age group in childhood, 3 to 12 years. Since the observations of those tonsillectomized within 30 days and over 30 days were made on children, the authors of this paper necessarily limited their conclusions to them. In great part the work of the undersigned, too, dealt primarily with poliomyelitis in children who in overwhelming degree—far greater than in the postvaccination period —were the chief victims of the disease. For the
Awards, Appointments, Announcements
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Awards, Appointments, Announcements Get access JNCI: Journal of the National Cancer Institute, Volume 85, Issue 14, 21 July 1993, Pages 1114–1116, https://doi.org/10.1093/jnci/85.14.1114-a Published: 21 July 1993